Satellos Bioscience Inc. (NASDAQ:MSLE, TSX:MSCL), a clinical-stage drug development company developing potentially life-improving medicines to treat degenerative muscle diseases, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,747,245, entitled "AP2 associated kinase 1 inhibitors and uses thereof." The patent includes composition of matter claims covering forazapadin, Satellos’ lead clinical-stage drug candidate, as well as a broader class of AAK1 inhibitors and related compounds within the company's muscle regeneration platform.

The composition of matter patent provides intellectual property protection through Sept. 6, 2044. In addition, the company may be eligible for a Patent Term Extension for forazapadin following future U.S. marketing approval, potentially extending patent protection beyond the current expiration date.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.